All Outputs (3)

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM) (2024)
Journal Article
Vasudev, N. S., Ainsworth, G., Brown, S., Pickering, L., Waddell, T., Fife, K., Griffiths, R., Sharma, A., Katona, E., Howard, H., Velikova, G., Maraveyas, A., Brown, J., Pezaro, C., Tuthill, M., Boleti, E., Bahl, A., Szabados, B., Banks, R. E., Brown, J., …Powles, T. (2024). Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology, 42(3), 312-323. https://doi.org/10.1200/JCO.23.00236

PURPOSE: Ipilimumab (IPI), in combination with nivolumab (NIVO), is an approved frontline treatment option for patients with intermediate- or poor-risk advanced renal cell carcinoma (aRCC). We conducted a randomized phase II trial to evaluate whether... Read More about Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians (2022)
Journal Article
Krajnik, M., Hepgul, N., Wilcock, A., Jassem, E., Bandurski, T., Tanzi, S., Simon, S. T., Higginson, I. J., Jolley, C. J., Arendt-Nowakowska, A., Bajwah, S., Bausewein, C., Bazata, J., Bolton, C., Bonelli, C., Brindle, R., Brown, S., Costantini, M., Currow, D., Dimbleby, C., …Walker, F. (2022). Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians. BMC Pulmonary Medicine, 22(1), Article 41. https://doi.org/10.1186/s12890-022-01835-0

Background: Respiratory medicine (RM) and palliative care (PC) physicians’ management of chronic breathlessness in advanced chronic obstructive pulmonary disease (COPD), fibrotic interstitial lung disease (fILD) and lung cancer (LC), and the influenc... Read More about Do guidelines influence breathlessness management in advanced lung diseases? A multinational survey of respiratory medicine and palliative care physicians.

Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility) (2020)
Journal Article
Higginson, I., Wilcock, A., Johnson, M. J., Bajwah, S., Lovell, N., Yi, D., Hart, S., Crosby, V., Poad, H., Currow, D., Best, E., & Brown, S. (2020). Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility). Thorax, 75(2), 176-179. https://doi.org/10.1136/thoraxjnl-2019-213879

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. New treatments are required for severe breathlessness in advanced disease. We conducted a randomised feasibility trial of mirtazapine over 28 days in adults with... Read More about Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility).